GLP‑1 medications changed what's possible in weight loss. Semaglutide and tirzepatide, the drugs behind Ozempic, Wegovy, Mounjaro and Zepbound, take 15 to 20% of body weight off in trials, results that used to require surgery. But the shot is only part of the job. What you do alongside it, and after it, decides whether the weight stays gone. A 2025 review in the journal Biomedicines lays out the rest, and it maps almost exactly onto what Omadic was built to deliver: pair the medication with intermittent fasting, protein‑forward eating, and licensed‑nurse oversight so the results actually hold.
What happens when you stop
GLP‑1s work while you take them. The review pulls the big trials together: semaglutide averaged a 14.9% weight loss in STEP‑1, tirzepatide reached up to 20.9% in SURMOUNT‑1, and the SELECT trial found about a 20% drop in major cardiac events. Powerful drugs.
The problem is what comes next. When the prescription ends, appetite returns and the weight comes back; the STEP‑4 trial showed it plainly. That rebound is biology, not a lack of willpower. The drug turns hunger down, so when it's gone the hunger returns, and unless new habits are already in place the body drifts back to where it started.
And most people do stop. The review reports up to half of users quitting within two years, worn down by the side effects, the injections, and a cost that often runs $800 to $1,200 a month, or as much as $4,000 to $12,000 a year. For most people the drug was never going to be forever, which makes what comes after it the part that really counts.
The weight that comes back is also worse than the weight that left. GLP‑1s strip away lean muscle along with fat, and muscle is what keeps your metabolism high, so once it's gone the rebound comes easier. Closing that gap between losing the weight and keeping it off is the whole reason Omadic exists.
What the research backs
The paper, "Added Value to GLP‑1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes," by Cozma, Văcărescu and Stoicescu, makes a clear case for treating a GLP‑1 as a head start rather than the whole plan. You use the appetite suppression to build a fasting routine and the habits that hold the result, then lean on the drug less over time.
The reasoning is that the two do different jobs: the medication quiets appetite while fasting works on your metabolism. Put them together, add enough protein and some resistance training, and you keep more weight off, hold on to more muscle, and tolerate the medication better. None of this is fringe; it's a peer‑reviewed framework, and it lines up almost point for point with how Omadic already coaches.
The review goes further on the payoff. Done right, the authors argue, this approach makes weight loss more durable, protects lean mass, and, for anyone tired of the needle, reduces how dependent you are on the drug over time, with the lower cost and the sense of control that come with it. The medication gets you moving; the lifestyle is what lets you eventually stand on your own. Used this way, you get everything the drug has to offer and a result that doesn't depend on it forever.
The fasting side of the plan
Fasting isn't one diet. The gentle version is time‑restricted eating: you keep your meals inside a daily window, 16 hours off and 8 hours on (16:8), then tighten it toward 18:6, 20:4, or one meal a day as it gets easier. Even a plain 8‑hour window produced a 2.6% weight loss in one study the review cites, and alternate‑day fasting improved blood pressure and cholesterol.
You don't jump to the deep end. You start where you are and shorten the window only when the last step feels easy, which is exactly how Omadic's plans are built. On a GLP‑1 it's far more doable, because the medication is already quieting the hunger that makes longer fasts hard.
Why they work so well together
Start with why the combination clicks. The hardest part of fasting is the first few hungry hours, and that's the part a GLP‑1 takes away: it dials down hunger and the pull of food cues, so getting into a fasting window stops being a fight. On its own, fasting takes off less weight and a lot of people quit early. On the medication, the thing that usually derails them is already handled.
Fasting then does the work the drug can't. While the medication is busy with appetite, fasting goes after your metabolism, burning fat, making ketones, and switching on the cellular cleanup (autophagy) that the review ties to healthier aging. Where the drug takes care of hunger, fasting reshapes the metabolism underneath it.
And the routine is what lasts. Set eating times and a daily rhythm stay in place long after the prescription ends, and that's the whole point. The habit is what turns a temporary result into a permanent one.
Don't lose the muscle
The one thing you can't get wrong is your muscle. Both GLP‑1s and aggressive fasting can burn lean tissue, so the plan has to protect it: enough protein in every eating window, and resistance training to tell your body to hold what it has. The review highlights a 2023 trial where adding exercise to a GLP‑1 stripped off more belly fat and improved metabolic health than the drug alone. Omadic tracks your protein and macros against goals built for exactly this, so what you lose is fat and not the muscle that keeps the weight off.
A licensed nurse runs your plan
This is the part most apps leave to you, and it's the part that decides how well the whole thing works. The review is clear that the approach works best when it's personalized and supervised: the dose, the fasting schedule, the side effects and the taper all need a steady, qualified hand. That's a strong argument for doing this with Omadic, where a licensed professional is built into the plan.
Every Omadic plan is overseen by licensed nurses and health professionals. They review your plan, match the fasting progression to your medication and titration, help you stay ahead of side effects like nausea instead of white‑knuckling through them, and guide the taper so you come off the drug without losing the result.
In practice, the plan moves with you. Say your dose goes up and your appetite falls off a cliff: your nurse shortens the fast and pushes protein that week so you don't bleed muscle. Get hit with nausea and they'll move your eating window rather than tell you to power through it. They watch for the scale dropping too fast, an early sign of lean‑mass loss, and ease off when it does. When you're ready to taper, they walk you down while the habits carry the result, coordinating with your prescriber rather than working around them. This is coaching and education alongside your medical team, never a replacement for it.
The research says to personalize and supervise. A licensed nurse in your corner is how Omadic does exactly that. The thing other apps bury in a disclaimer, we built into the product.
The Omadic method, start to finish
Put it together and the path is simple:
- Start on the medication while hunger is low, and use that window to build a fasting routine and a protein‑first way of eating, with a nurse setting the plan.
- Lock in the habits: steady eating windows, regular training, and enough protein, all tracked in the app and adjusted as you go.
- Taper with guidance so the routine carries the result and the weight stays gone.
That's the GLP‑1 off‑ramp Omadic is built around: guided fasting plans that grow with you, a medication and supplement tracker that follows your dose, titration and reminders, protein tracking that protects your muscle, real‑time alerts on your watch, and licensed‑nurse coaching through every step.
A GLP‑1 gets you started, and the lifestyle is what makes the result last. What makes it safe is a licensed nurse watching the whole thing. The science has caught up to what we already believed; now it comes down to doing it right.
Common questions
Can you do intermittent fasting on Ozempic, Wegovy or Mounjaro? For most people, yes — and the medication usually makes it easier, because it's already taking the edge off your hunger. The thing to watch is that GLP‑1s and fasting can share side effects like nausea, so the schedule should fit how the drug actually affects you. Dialing that in is exactly the kind of thing an Omadic nurse helps with.
Will a GLP‑1 make me lose muscle? It can. Fast weight loss on these drugs takes some lean tissue along with the fat, which is why protein and resistance training matter so much on this approach. Omadic tracks your protein against goals built to protect muscle, so more of what you lose is fat — and more of your result holds when you taper.
How long should I fast if I'm on a GLP‑1? Start gentle. A 12‑ or 14‑hour overnight window is plenty at first, and you extend only when it genuinely feels easy. Longer isn't automatically better, especially when the medication is already changing your appetite and digestion. Your nurse matches the progression to your dose so you're never pushing too hard.
Do I have to come off the medication? No — but most people want to eventually, and that's where this matters most. Building the fasting habit while you're still on the drug means you have something real to fall back on when you taper, so the weight doesn't come straight back the moment you stop.
Is Omadic a replacement for my prescriber? Not at all. Omadic's nurses coach the lifestyle side and coordinate with your medical team — they don't prescribe or change your medication. It's the support around the prescription, not a substitute for it.
New to fasting? Start with how to break a fast the right way and why electrolytes matter on longer fasts.
Sources
- Cozma D, Văcărescu C, Stoicescu C. Added Value to GLP‑1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes. Biomedicines. 2025;13(12):3079. Journal (MDPI) · Full text (PubMed Central)
- Trials drawn on in the review: Wilding et al., STEP‑1 (semaglutide), New England Journal of Medicine, 2021; Jastreboff et al., SURMOUNT‑1 (tirzepatide), New England Journal of Medicine, 2022; Lincoff et al., SELECT (cardiovascular outcomes), New England Journal of Medicine, 2023; Rubino et al., STEP‑4 (weight regain after stopping), JAMA, 2021.
- de Cabo R, Mattson MP. Effects of Intermittent Fasting on Health, Aging, and Disease. New England Journal of Medicine, 2019.